Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial

Lancet Infectious Diseases
Dec 2021 Volume 21 Number 12 p1613-1758, e363-e406
https://www.thelancet.com/journals/laninf/issue/current

 

Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial
Shipo Wu, et al.